Novavax Financial Statements
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novavax revenue and earnings
In fiscal 2025, Novavax generated $1.12 billion in revenue, up 64.7% from fiscal 2024. Net income was $440.3 million, for a net margin of 39.2% versus a median of -55.4% in the prior 5 years. Gross margin was 93.5% (up from 70.3%) and operating margin 40.3%.
Diluted earnings per share came in at $2.58. Over the last 5 fiscal years, NVAX's revenue has grown at a 18.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Novavax income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.12B | 682.16M | 983.71M | 1.98B | 1.15B | 475.60M | 18.66M | 34.29M | 31.18M | 15.35M |
| Revenue growth (YoY) | +64.69% | -30.65% | -50.36% | +72.89% | +141.02% | +2448.48% | -45.57% | +9.98% | +103.06% | -57.65% |
| Cost of Revenue | 73.04M | 202.74M | 343.77M | 902.64M | 0 | 0 | — | — | — | — |
| Gross Profit | 1.05B | 479.42M | 639.94M | 1.08B | 1.15B | 475.60M | — | — | — | — |
| Operating Expenses | 597.64M | 728.35M | 1.21B | 1.72B | 2.83B | 892.32M | — | — | — | — |
| Research & Development | 342.32M | 391.17M | 737.50M | 1.24B | 2.53B | 747.03M | 113.84M | 173.80M | 168.44M | 237.94M |
| Selling, General & Admin | 157.48M | 337.19M | 468.95M | 488.69M | — | — | — | — | — | — |
| Operating Income | 452.80M | -248.93M | -566.51M | -644.74M | -1.69B | -416.72M | -120.58M | -173.92M | -171.71M | -269.11M |
| Interest Expense | 22.55M | 20.07M | 14.42M | 19.88M | 21.13M | 15.14M | 13.61M | 13.61M | 14.07M | 12.96M |
| Other Income (Expense) | 40.63M | 40.44M | 37.90M | 10.97M | -6.83M | 13.61M | -13.00K | 108.00K | 67.00K | -31.00K |
| Pretax Income | 442.17M | -176.62M | -543.03M | -653.65M | -1.71B | -418.26M | -132.69M | — | — | — |
| Income Tax | 1.86M | 10.88M | 2.03M | 4.29M | 29.21M | 0 | 0 | — | — | — |
| Net Income | 440.30M | -187.50M | -545.06M | -657.94M | -1.74B | -418.26M | -132.69M | -184.75M | -183.77M | -279.97M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 2.72 | -1.23 | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 | -9.99 | -12.56 | -1.03 |
| EPS (Diluted) | 2.58 | -1.23 | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 | -9.99 | -12.56 | -1.03 |
| Shares Outstanding (Basic) | 161.99M | 152.19M | 100.77M | 78.18M | 74.40M | 57.55M | 24.10M | 18.49M | 14.63M | 270.80M |
| Shares Outstanding (Diluted) | 173.10M | 152.19M | 100.77M | 78.18M | 74.40M | 57.55M | 24.10M | 18.49M | 14.63M | 270.80M |
| EBITDA | 480.80M | -200.93M | -525.51M | -615.74M | -1.67B | -412.42M | -115.48M | -166.52M | -164.11M | -261.41M |
| Gross Margin | 93.50% | 70.28% | 65.05% | 54.46% | 100.00% | 100.00% | — | — | — | — |
| Operating Margin | 40.30% | -36.49% | -57.59% | -32.53% | -147.13% | -87.62% | -646.13% | -507.23% | -550.78% | -1752.84% |
| Net Margin | 39.19% | -27.49% | -55.41% | -33.20% | -152.12% | -87.94% | -711.04% | -538.81% | -589.46% | -1823.53% |
This table shows 10 annual periods of Novavax's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NVAX's reporting calendar. What is a income statement?